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ABSTRACT 
Neuroblastoma is one of the most common solid neoplasms in children, which 
affects sympathetic neurons with a wide range of genetic abnormalities, especially 
MYCN amplification, a molecular marker of poor prognosis. Despite advance therapy, 
still the mortality rate for advance disease is high with frequent relapse and resistance to 
cytotoxic therapy with evidence of p53 mutation. Metformin, an oral hypoglycemic 
medication, is a relatively safe and cost effective drug with wide clinical applications, 
mainly for treatment of Type 2 diabetes. Recent studies have showed promising 
anticancer effect of metformin on various cancer types, especially on p53 mutant cells. In 
our research, we performed in vitro study testing the effect of metformin on 
neuroblastoma cells, as little is known about its effect on this disease. Our results 
demonstrate that metformin at 10 and 20 mM has significant growth and survival 
inhibitory effects on both N-myc amplified and N-myc non-amplified and p53 mutant 
cells. Metformin induces apoptosis in both cell types revealed by morphological changes 
and detection of cleaved caspase3 by western blot analysis. Metformin’s anticancer effect 
may be independent on AMPK and AKT pathways as our initial results show no marked 
change relative to control. Metformin decreases total RhoA protein expression in both 
cell lines and total Rac1 protein expression in N-myc amplified cells. Our results suggest 
that metformin can be a good and safe candidate for treatment of neuroblastoma.                                                  
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CHAPTER 1 
INTRODUCTION 
1.1 Neuroblastoma: 
Neuroblastoma is the third most prevalent childhood malignancy, after acute 
lymphocytic leukemia (ALL) and CNS and brain tumors, and it is the commonest 
neoplasm encountered in children below one year of age (American Cancer Society, 
2014;Chakrabarti, Abou-Antoun, Vukmanovic, & Sandler, 2012). Neuroblastoma 
represents 7% of all childhood malignancy and up to 15% of cancer related mortality 
(American Cancer Society, 2014; Davidoff, 2012). In the United States, around 700 new 
cases of neuroblastoma are diagnosed each year with approximate incidence of 10.2 cases 
per1,000,000 children below 15 years old (Davidoff, 2012; Cheung & Dyer, 2013). 
Neuroblastoma is a heterogeneous embryonic tumor affecting postganglionic 
sympathetic neurons with wide variety of clinical presentations and genetic aberrations 
(Normand, Michon, Janoueix-Lerosey, Delattre, & Schleiermacher, 2011). It generally 
tends to affect males slightly more than females and white children more than other races 
(American Cancer Society, 2014) . Neuroblastoma disease could in some cases regress 
spontaneously or it can undergo differentiation into more benign form ganglioneuromas 
(Weinstein, Katzenstein, & Cohn, 2003) . However, up to half of cases are associated 
with metastatic presentations at time of diagnosis with overall survival rate around 40% 
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(Matthay, Weiss, et al., 2012). Most cases of neuroblastoma are sporadic with various 
genetic abnormalities, and no definitive environmental factors have been found 
predisposing to its development (Weinstein et al., 2003). On the other hand, only 1- 2% 
of neuroblastoma are familial cases with early onset of the disease and with multiple 
primary tumor foci detected at time of diagnosis (Maris et al., 2002). 
Despite the increase in the survival rates of neuroblastoma in general (around 
79% survival rate during 2003-2009 compared to the 54% in the previous years), the 
survival rate of high risk neuroblastoma patients remains low, with increased morbidity 
due to complications of intensified chemotherapeutic treatment (American Cancer 
Society, 2014). 
1.1.1 Pathogenesis and genetic abnormalities: 
Neuroblastoma is a malignant tumor involving sympathetic neurons, mainly 
adrenal medulla and paraspinal sympathetic nerves (Normand et al., 2011). 
Neuroblastoma originates from sympathoadrenal precursor cells which are derived from 
neural crest cells (Cheung & Dyer, 2013). Neural crest cells are group of embryonic cells 
which are found in neural plate border region of developing embryo (Dupin & Sommer, 
2012). These neural crest cells can give rise to different cell types, such as: melanocytes 
of epidermis, smooth muscle cells of vessels, craniofacial bone, glia and Schwann cells, 
enteric and peripheral neurons, olfactory cells, adipocytes, meninges and adrenal medulla 
(Cheung & Dyer, 2013; Dupin & Sommer, 2012). During embryonic development, some 
of neural crest cells migrate from their original site to the dorsal aorta where they become 
sympathoadrenal lineage cells (Cheung & Dyer, 2013). In turn, sympathoadrenal 
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precursor cells further differentiate, in response to many signals, into paraspinal 
sympathetic ganglia or chromaffin cells comprising adrenal medulla(Cheung & Dyer, 
2013). 
 
Figure 1.1 “Development of the lineages derived from neural crest cells and the origin of 
the different stages of neuroblastoma (NB)”. Reused from “Neuroblastoma therapy: what 
is in the pipeline?” by Verissimo, C. S., Molenaar, J. J., Fitzsimons, C. P.,& Vreugdenhil, 
E. (2011). Endocr Relat Cancer, 18(6), R213-231, figure 1. doi: 10.1530/ERC-11-0251 
Copyright © [2011] [BioScientifica Ltd]. Reused with permission.   
Several signaling pathways and genes are well regulated during embryogenesis 
and contribute to accurate differentiation of these precursor cells to become specialized 
neuronal cells, such as: paired-like homeobox2b (PHOX2B), which is important for 
neuronal cells differentiation, and anaplastic lymphoma receptor tyrosine kinase (ALK) 
4 
 
gene, which control MAPK and RAS-related protein 1 (RAP1) signaling pathways in 
order to regulate neuronal cell proliferation and differentiation (Cheung & Dyer, 2013; 
Verissimo, Molenaar, Fitzsimons, & Vreugdenhil, 2011). Similarly, MYCN proto-
oncogene, located on chromosome 2p24, is found to be involved in neuronal precursor 
cells proliferation and inhibition of their differentiation during embryogenesis(Davidoff, 
2012; Verissimo et al., 2011). 
Although the exact genetic causes of neuroblastoma are not well understood, 
disruption or overexpression of these signaling factors are linked to the development of 
neuroblastoma, besides other genetic aberrations (Santo et al., 2013).In familial 
neuroblastoma, two common mutations can be found: mutation in paired-like 
homeobox2b (PHOX2B) gene, or more commonly ALK gene mutation in germ line 
which  is also found as a somatic cell mutation or amplification in approximately 8% of 
sporadic neuroblastoma cases (Cheung & Dyer, 2013; Van Roy et al., 2009). Besides, 
several genetic abnormalities are encountered in most neuroblastoma cases, especially in 
advance stages, including: DNA ploidy, chromosomal loss, mutations of specific genes, 
and most importantly MYCN amplification (Davidoff, 2012). N-myc proto-oncogene, a 
transcription factor belongs to the basic-helix-loop-helix-zipper (bHLHZ) class, is 
amplified in about 22% of neuroblastoma cases, predominately in metastatic disease, and  
associated with poor prognosis (Knoepfler, Cheng, & Eisenman, 2002; Cheung & Dyer, 
2013). MYCN amplification in neuroblastoma can be found in two different forms: extra-
chromosomal fragments as double-minute chromatin bodies (DMs), or homogeneously 
staining regions (HSRs) within the chromosome (Davidoff, 2012). N-myc, which is 
commonly amplified in advance neuroblastoma, can heterodimerize with MAX protein in 
5 
 
DNA specific sequences and promote transcription (Knoepfler et al., 2002). However, the 
exact contribution of MYCN amplification to the development of  aggressive 
neuroblastoma, which is associated with poor outcome , remains unknown (Van Roy et 
al., 2009). Other genetic abnormalities commonly detected in neuroblastoma include: 
change in the number of chromosomes or individual chromosomal abnormalities, which 
associate with various outcomes(Normand et al., 2011). DNA ploidy generally refers to 
the DNA content within the cell (2 copies of each 23 chromosomes are normally found in 
diploid cells) (Davidoff, 2012). In primary neuroblastoma disease, up to 55% of cases 
contain near triploid or triploid cells, while the rest 45% cases harbor near-diploid or 
near-tetraploid cells(Davidoff, 2012). Similarly, chromosomal   abnormalities  frequently 
encountered  in neuroblastoma are: gain of  chromosome 17q and loss of chromosomal 
regions 1p,11q, and 3p (Normand et al., 2011). Chromosome 17q gain are found in up to 
80% of cases due to unequal translocation with other chromosomes (chromosome 1p or 
chromosome 11q) in tumor cells (Van Roy et al., 2009). Another common chromosomal 
abnormality is loss of chromosome1p in up to 25-35% of cases, which may contain 
cancer suppressor genes (Van Roy et al., 2009). Deletion of chromosome 1p is frequently 
detected in neuroblastoma cases, particularly in advanced disease when it commonly 
correlate with MYCN amplification (Davidoff, 2012; Van Roy et al., 2009). Moreover, 
several other chromosomal loss, which might contain cancer suppressor genes, are 
frequently found in neuroblastoma tumor without association with MYCN amplification, 
these include: chromosome 11q loss commonly found in high stage neuroblastoma, and 
chromosome 3p loss in association with loss of chromosome 11q commonly found in 
older patients (Van Roy et al., 2009). 
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Genetic mutations in neuroblastoma is not only confined to the primary tumor but 
also can be found after cytotoxic therapy in relapsed neuroblastoma (Carr-Wilkinson et 
al., 2010; Tweddle, Malcolm, Bown, Pearson, & Lunec, 2001). Mutations in p53, a tumor 
suppressor gene located on short arm of chromosom17, are rare in primary 
neuroblastoma at time of diagnosis (Tweddle et al., 2001). However, several studies have 
shown that p53 mutations could be found in relapsed neuroblastoma after chemotherapy 
(Tweddle et al., 2001; Carr-Wilkinson et al., 2010). P53 is a transcription factor that 
binds specific DNA sequence and promotes transcription of p21, MDM2 and BAX genes 
in response to DNA damage, which in turn involve in regulation of cell cycle and 
apoptosis (Tweddle et al., 2001; Carr-Wilkinson et al., 2010). In neuroblastoma cells 
from relapsed cases, it was found that p53 is frequently inactivated by genetic mutation 
or the p53/MDM2/p14ARF pathway that control p53 in the cell is mutated.(Tweddle et al., 
2001; Carr-Wilkinson et al., 2010). These genetic abnormalities are used clinically as 
prognostic markers, especially MYCN amplification, in diagnosis, staging, and prediction 
of prognostic outcome of the patient (Lonergan, Schwab, Suarez, & Carlson, 2002). In 
addition they are used to determine the appropriate strategy for treatment, which range 
from observation and surgery alone for low risk patients to the use of more intensified 
cytotoxic therapy for high risk disease (Davidoff, 2012).  
1.1.2 Clinical presentations of neuroblastoma: 
Neuroblastoma is the most frequently encountered extracranial solid malignancy 
in children, and it is mainly diagnosed during infancy and in children below 5 years 
(around 90%) (Van Roy et al., 2009; Verissimo et al., 2011). The median age of 
diagnosis is around 18 months for sporadic cases, while in familial neuroblastoma it is 
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around 9 months with frequent presentation of bilateral or multifocal malignancy 
(Brodeur, 2003). Neuroblastoma can develop in different places along the sympathetic 
neurons but the majority arises in the lumber sympathetic neurons and adrenal medulla 
(around 65%), whereas the rest cases can occur anywhere through the sympathetic 
neurons in chest, neck, or pelvic regions in a ratio of 4/1/1, respectively (Cheung & Dyer, 
2013). 
The clinical presentations of neuroblastoma vary depending on the effect of  
primary tumor and distant metastasis(Maris, 2010; Papaioannou & McHugh, 2005; 
Papaioannou & McHugh, 2005). The primary tumor usually presents as palpable mass in 
the abdomen, especially in case of adrenal involvement, or mass in the neck or chest due 
to involvement of corresponding sympathetic neurons (Maris, 2010). In addition, 
neuroblastoma growth may involve vital structures or press the surrounding tissues, blood 
vessels, and nerves, especially in high stage disease, which can lead to various signs and 
symptoms, including: blood vessels involvement such as renal arteries, Horner’s 
syndrome due to involvement of cervical neurons, and pressure effect of growing tumor 
on spinal cord which leads to various neurological defects (Papaioannou & McHugh, 
2005). 
 In neuroblastoma cases with metastasis, infiltration of surrounding tissues can 
lead to various presentations, such as: liver enlargement especially in stage 4S disease, 
blindness due to involvement of optic nerve, lymph node enlargement, and infiltration of 
bone marrow with fever, malaise, anemia and bone pain.(Papaioannou & McHugh, 
2005). 
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1.1.3 Diagnosis, Staging and risk group classification: 
         Diagnosis of neuroblastoma is based mainly on histopathological examination, bone 
marrow aspiration, laboratory tests and radiological investigations which also help in 
disease staging and predicting patient outcome (Weinstein et al., 2003). Ultrasonography 
is the initial technique commonly used to detect abdominal neuroblastoma mass and 
determine its location, similarly, plain radiograph is helpful in the detection of primary 
tumor and metastasis (Papaioannou & McHugh, 2005). However, CT scan and MRI are 
the main techniques used for definitive diagnosis and staging of the disease, beside, 
Scintigraphy ,using 99mTc-MDP and 123I-MIBG, is commonly used for diagnosis of 
primary tumor and searching for metastatic lesions (Papaioannou & McHugh, 2005; 
Weinstein et al., 2003). Laboratory tests frequently used in diagnosis of neuroblastoma 
include: histochemical testing of bone marrow sample and urinary testing of 
catecholamine level(Papaioannou & McHugh, 2005). Histological examination of 
neuroblastoma generally reveals presence of undifferentiated small round neuronal cells 
(Neuroblastoma cells), and in some cases tumor cells exhibits mild degree of histological 
differentiation (ganglioneuroblastomas) (Brodeur, 2003). On the other hand, in the more 
mature form of the disease the histological examination shows mature neuronal cells 
within Schwann rich stroma (Brodeur, 2003). 
Generally, neuroblastoma is classified into favorable and unfavorable 
histopathological prognostic groups based on Shimada histopathological classification in 
1984(Weinstein et al., 2003). This classification takes into account age of the patient at 
time of diagnosis (<1.5 years,1.5–5 years, or >5 years) and histologic criteria including: 
presence of schwannian stroma whether rich (mature) or poor (immature), degree of 
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cellular differentiation (undifferentiated, differentiated or mixed), and the mitosis and 
karyorrhexis index (MKI) (low, intermediate and high) (Lonergan et al., 2002; Weinstein 
et al., 2003). MKI represents the summation of tumor cells with mitosis and karyorrhexis 
per 5,000 cells sample (Lonergan et al., 2002). According to this classification, patients 
with favorable histopathology are those who are < 1.5 years old with at least partially 
differentiated tumor and low or intermediate MKI or those who are 1.5–5 years old with 
differentiated tumor and a low MKI , however, the remaining groupings are classified as 
unfavorable histopathology (Lonergan et al., 2002). 
Furthermore, neuroblastoma is commonly classified into different stages based on 
clinical, surgical and radiologic criteria of the International Neuroblastoma Staging 
System (INSS), established in 1988 and modified in 1993(Lonergan et al., 2002; 
Weinstein et al., 2003). In this staging system, the classification of neuroblastoma 
generally ranges from stage1 disease, in which tumor is localized and carry good 
prognosis, to stage 4 disease, in which tumor is metastasized and carry poor 
prognosis.(Lonergan et al., 2002; Weinstein et al., 2003). In addition, there is another 
stage called stage 4S (stage 4 “special”) represents 7-10% of neuroblastoma cases and 
includes the following criteria: presence of small primary tumor, age <12 months, and 
evidence of distance metastasis confined to the liver, skin and <10% of bone marrow, 
which generally carries good prognosis with disease free survival rate up to 57–87% 
(Schleiermacher et al., 2003). 
In 2009, International Neuroblastoma risk group staging system (INRGSS) 
classifies neuroblastoma into 4 stages (L1, L2, M, and MS) using radiographic 
investigation, and this classification is based mainly on extent, stage, and risk factors of 
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the tumor (Cohn et al., 2009; Van Roy et al., 2009). L1 and L2 denote local disease, M 
for metastatic tumor, and MS for tumor encountered in children below18 months with 
similar stage 4S metastatic criteria (Cohn et al., 2009; Van Roy et al., 2009). Based on 
this staging system and molecular prognostic factors, neuroblastoma is further classified 
according to International Neuroblastoma Risk Group (INRG) Pretreatment 
Classification into 4 main categories (very low, low, Intermediate, and high risk) with 16 
pretreatment groups (A-R), to determine overall prognosis and suitable treatment for 
patients (Cohn et al., 2009). According to this classification, the overall 5 years event free 
survival (EFS) for patients with very low risk group (A, B, C) about 85%,  low risk 
group(D, E, F)75%-85%, intermediate risk group (G, H, I, J) 50% -75%, and high risk 
group (K, N, O, P, Q, R) below 50% (Cohn et al., 2009).  
1.1.4 Treatment of neuroblastoma: 
Current treatment of neuroblastoma is based on children’s oncology group (COG) 
neuroblastoma risk classification, in which patients are categorized into 3 major groups: 
low risk group, intermediate risk group, and high risk group (Davidoff, 2012). This risk 
group classification is based on various prognostic criteria, including: stage of the tumor, 
age of the patient at time of diagnosis, presence of MYCN amplification, DNA ploidy 
status, histological features (favorable or unfavorable histology), and others including the 
percent of tumor which is resected (Henderson et al., 2011). Patients with low risk 
neuroblastoma are those with stage1, stage 2A/2B with > 50% of tumor resected, or stage 
4S diseases with favorable histology and DNA Index(DI) >1, and all these stages without 
evidence of MYCN-amplification (Davidoff, 2012; Henderson et al., 2011). Intermediate 
risk group includes patients up to one year old with stage 2A/2B disease and the tumor 
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undergo biopsy only or <50% resected, patients up to1.5 years with stage 3 tumor, those 
between 1.5-12 years old with stage 3 disease and favorable histology, patients 1-1.5 
years with stage 4 disease and favorable histology with DI >1, or symptomatic patients 
with stage 4S and unfavorable histology or DI equal to 1, and all these stages without 
MYCN amplification(Davidoff, 2012; Henderson et al., 2011). High risk group are those 
with stage 4 disease and > 1.5 years old, patients with stage(2A/2B,3,4, or 4S) with 
evidence of MYCN amplification, patient with stage 3 with unfavorable histology and 
>1.5 years old, or patients between 1-1.5 years old with advance stage 4 disease that has 
either unfavorable histology or DI=1 (Davidoff, 2012; Henderson et al., 2011). 
Accordingly, low risk group patients are generally treated with surgery alone, or 
sometimes observation and biopsy, especially for infant with favorable stage 4S disease 
(Davidoff, 2012). Intermediate-risk groups are treated with chemotherapy and surgical 
removal of resectable tumor, while those with high-risk illness generally require intensive 
chemotherapy (myeloablative therapy), stem cells transplantation, radiotherapy and 
reducing tumor mass surgically (Davidoff, 2012). 
However, more than 50% of high risk cases relapse and develop resistance to 
chemotherapy after initial response (Carr-Wilkinson et al., 2010). In recent years, more 
efforts have been made to develop targeted therapy in order to improve the treatment of 
neuroblastoma, which ultimately may lead to increase overall survival of the patients 
(Matthay, George, & Yu, 2012). One of these approaches depends on using small 
molecules to inhibit ALK, a tyrosine kinase commonly mutated in familial neuroblastoma 
and in up to 6-10% of sporadic cases (Cheung & Dyer, 2013; Matthay, George, et al., 
2012). The second approach is by immune destruction of cancer cells using antibodies 
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specific for GD2 a (Disialoganglioside), a specific cell surface antigen presenting in 
around 98% of neuroblastoma cases(Davidoff, 2012);(Cheung & Dyer, 2013; Matthay, 
George, et al., 2012). Another recent approach is to use 131I-metaiodobenzylguandine 
(MIBG) (norepinephrine analogue) commonly used for staging of neuroblastoma disease 
(Matthay, Weiss, et al., 2012). This therapy targets norepinephrine transporter expressed 
in around 90% of  neuroblastoma cancer cells, then these cancer cells are destroyed using 
radiotherapy(Matthay, George, et al., 2012; Matthay, Weiss, et al., 2012). These targeting 
therapies for the treatment of  neuroblastoma disease are being used in early clinical trials 
with promising results, however, each one of these therapy may cause considerable side 
effects, such as  the risk of radiation accompany MIBG therapy and cell toxicity 
accompany anti GD2 immunotherapy, which require further evaluation of these new 
approaches to minimize their adverse effects (Matthay, George, et al., 2012). 
1.2 Metformin: 
Metformin (N’,N’-dimethylbiguanide) is the most commonly used oral 
hypoglycemic medication in the treatment of non-insulin dependent (type2) diabetes 
mellitus worldwide (Ben Sahra, Le Marchand-Brustel, Tanti, & Bost, 2010; Gong, 
Goswami, Giacomini, Altman, & Klein, 2012). Metformin belongs to biguanide family, 
which also includes two other compounds phenformin and buformin (Dowling, Goodwin, 
& Stambolic, 2011). Metformin is originally derived from the French Lilac herb (Galega 
officinalis) and was used as a herbal tea during the medieval Europe and ancient Egypt to 
treat symptoms similar to type 2 diabetes, including polyuria and halitosis (Dowling et 
al., 2011). Biguanide contains guanidine active component that was first discovered in 
1900s to have antidiabetic proprieties, which eventually lead to the synthesis of 
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metformin and phenformin to be used clinically as antidiabetic drugs(Quinn, Kitagawa, 
Memmott, Gills, & Dennis, 2013). Phenformin was used in the USA from 1957-1970s 
when it was discontinued due to its side effect of sever lactic acidosis (Quinn et al., 
2013). On the other hand, metformin has been used to treat diabetic patients in Britain 
since 1958 and in Canada since 1972, while it was first approved in the united states in 
1995, due to its effectiveness and safety with the fact that the risk of lactic acidosis 
associated with metformin treatment is very low (less than 1 per 10,000), mainly in 
patients with impaired renal function (Ben Sahra et al., 2010; Dowling et al., 2011). 
Besides, more than 120 million prescriptions per year of metformin are used worldwide, 
and up to 40 million prescriptions of metformin were recorded in 2008 in the United 
States alone, due to its important role in treating diabetes and improving the survival of 
diabetic patients  (Dowling et al., 2011; Kourelis & Siegel, 2012). 
1.2.1 Pharmacological proprieties of metformin: 
           Metformin is given usually as an oral tablet,(Metformin HCL with MW 165.63),in 
a dose ranging between 1500-2250 mg/day for adult, with an average plasma half-life 
about 5 hours after administration (Graham et al., 2011; Dowling et al., 2011; Gong et al., 
2012). Metformin is positively charged molecule with hydrophilic properties, so it 
requires transporters to enter cell membrane (Graham et al., 2011). After administration, 
it is absorbed by gut plasma membrane and this may be through  plasma membrane 
monoamine transporters( PMAT), which are found mainly on luminal side of enterocytes, 
or may be through OCT1 or OCT3 Organic Cation Transporters (Gong et al., 2012). Peak 
plasma level of metformin in diabetic patients after one dose is about 0.5-2µg/ml or 
around 4-15 µM, and then metformin is distributed and  accumulated in different parts of 
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body tissues, including: kidneys, salivary gland, duodenum, stomach, and  liver (Quinn et 
al., 2013). Metformin is distributed to the liver mainly through OCT1 transporters which 
are found on the basolateral side of plasma membranes of hepatocytes, and may be 
through OCT3 transporters which are also localized on basolateral side of these cells 
(Gong et al., 2012). Metformin is distributed to other body tissues including heart, 
muscle, and adrenal glands which express OCT1 and/or OCT3 transporters (Graham et 
al., 2011). In addition, metformin uptake by the kidney is mainly through OCT2 
transporters presented on basolateral side of plasma membrane of renal tubular cells, and  
is excreted from the kidney via MATE1 and MATE2-K located on the apical membrane 
of the renal proximal tubules, when metformin is then eliminated in the urine as 
unchanged drug (Graham et al., 2011; Gong et al., 2012). 
1.2.2 Metformin’s role in diabetic and non-diabetic insulin resistance 
diseases: 
Metformin is commonly used to treat type2 diabetes, which is characterized by 
insulin resistance in peripheral tissue and associated hyperglycemia, without causing 
considerable hypoglycemia or weight gain compared to sulfonylurea (Graham et al., 
2011; Pollak, 2012). Metformin exerts its antidiabetic action through reduction in hepatic 
gluconeogenesis, increasing in peripheral tissue sensitivity to insulin, and increasing in 
tissues use of glucose, particularly in muscle and adipose tissues (Gong et al., 2012; Ben 
Sahra et al., 2010). 
In the liver, metformin reduces gluconeogenesis by targeting mitochondrial 
oxidative phosphorylation mainly through  affecting respiratory chain complex 1, or 
possibly by other indirect mechanisms (Dowling et al., 2011; Pollak, 2012). Ultimately 
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metformin treatment leads to decrease in ATP production and increase in AMP and ADP 
level (Quinn et al., 2013). The elevated AMP/ATP or ADP/ATP ratio leads to activation 
of AMP-activated protein kinase AMPK, which can sense low energy condition (Quinn 
et al., 2013). AMPK is a heterotrimeric serine/threonine protein kinase that has three 
distinct catalytic and regulatory subunits including: α-subunit (with 2 isoforms), β 
subunits (with 2 isoforms) and γ subunit (with 3 isoforms) (Quinn et al., 2013; Towler & 
Hardie, 2007). AMP nucleotides activate AMPK by both allosteric binding to the enzyme 
and by making it a good substrate to be phosphorylated by Liver Kinase 1 (LKB1), which 
is the AMPK upstream kinase (Towler & Hardie, 2007). The activated (phosphorylated) 
AMPK in turns affects different downstream targets to reduce mainly gluconeogenesis 
and fatty acid and protein synthesis (Dowling et al., 2011). Activated AMPK leads to 
inhibition of major gluconeogenesis genes and glucose production, inhibition SREBP-1 
gene expression (lipogenic transcription factor) and decrease lipid synthesis, and 
inhibition ACC (acetyl-CoA carboxylase enzyme) and fatty acid synthesis (Quinn et al., 
2013). However, recent study suggests that metformin can directly inhibit glucagon/PKA 
signaling pathway that leads to inhibition of gluconeogenesis independent on AMPK 
activation (Quinn et al., 2013). 
In addition to its role in diabetes, metformin in many studies help in reducing 
overall hyperinsulinemia and insulin resistance commonly found in patients with non-
diabetics insulin resistance diseases, including : the use of metformin in the management 
of polycystic ovarian diseases (PCOS), which is characterized by anovulation, excess 
androgen and polycystic ovaries, and in the clinical trial for non- alcoholic fatty liver 
diseases (NAFLD), which is characterized by fatty liver changes accompanied metabolic 
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syndrome in absence of  high alcohol consumption (Lashen, 2010; Mazza et al., 2012). 
Moreover, recent clinical trial regarding the use of metformin in obese children with 
insulin resistance demonstrated that metformin treatment associated with moderate effect 
on body weight and composition in these children (Yanovski et al., 2011).  
1.2.3 Metformin’s role in cancer: 
In recent years, several epidemiological studies have linked metformin treatment 
to lower incidences of cancer and cancer related mortality among diabetic patients (Ben 
Sahra et al., 2010). Besides, these studies compare incidence of cancer risk among those 
who are on metformin treatment with those who are on other antidiabetic medication 
(Ben Sahra et al., 2010). In 2005, Evan et al published a pilot case-control study 
regarding metformin treatment and cancer risk in patients with type 2 diabetes who 
resided in Scotland, Tayside during 1993-2001 years, and the results suggested that 
metformin treatment was correlated with low cancer risk among those patients (Viollet et 
al., 2012; Evans, Donnelly, Emslie-Smith, Alessi, & Morris, 2005). These results are 
followed by several epidemiological studies to test the role of metformin as anticancer 
medication, for instance, in 2006, a published population-based cohort study found that 
patients with type2 diabetes on sulfonylurea or insulin therapy have higher risk of cancer 
death rate compared to those using metformin (Bowker, Majumdar, Veugelers, & 
Johnson, 2006). Moreover, In 2012, Noto et al published a systemic review and meta-
analysis of several published articles regarding metformin and cancer risk, and they 
found that metformin was markedly associated with reduced incidence of cancer among 
diabetic patients (Noto, Goto, Tsujimoto, & Noda, 2012). Similarly, In 2013, another 
detailed systemic review was published including wide range of studies, conducted 
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during 1966-2012, regarding the use of metformin and other hypoglycemic agents among 
diabetic patients and their correlation with cancer risk (Franciosi et al., 2013). This 
review showed that metformin might have a correlation with lower incidence of different 
cancer types and associated cancer death (Franciosi et al., 2013).  
In addition, several in vitro, in vivo, and clinical studies have been conducted in 
recent years, exploring the role  of metformin as anti-cancer agent for different cancer 
types, and investigating the underlying molecular mechanisms (Pollak, 2012). In vitro 
studies using metformin, with dose typically ranging between 5-30 mM, demonstrated 
that metformin was able to inhibit cell growth in different cancer cell types such as lung, 
colon, and pancreatic cancers (Ben Sahra et al., 2010). Besides, some in vitro studies 
showed that metformin can induce apoptosis in different cell lines including triple 
negative breast cancer and pancreatic cancer (B. Liu et al., 2009; Kourelis & Siegel, 
2012; Ben Sahra et al., 2010). 
 Likewise, in vivo results using different cancer animal models demonstrated that 
metformin treatment was able to reduce tumor growth significantly in wide range of 
cancers, for instance, lung, colon, prostate, and triple negative breast cancer (Ben Sahra et 
al., 2010; Kourelis & Siegel, 2012). Moreover, metformin at very low concentrations 
specifically reduced growth of CD133+ pancreatic cancer stem cells (Gou et al., 2013). In 
addition, metformin treatment was selectively able to impair cell growth in p53 mutant 
colonic cancer (colon cancer) established in xenograft mice than p53 non mutant. (Buzzai 
et al., 2007). 
18 
 
The overall in vitro and in vivo studies suggest that metformin inhibits cell growth 
and/or induces apoptosis through two possible ways: indirect (insulin dependent) and 
direct (insulin independent) mechanisms (Dowling et al., 2011). Indirect mechanism 
depends on the systemic effect of metformin in lowering insulin level through reduction 
of hepatic glucose output and increasing tissue sensitivity to insulin (Dowling et al., 
2011; Kourelis & Siegel, 2012).  
 
 
Figure 1.2 “Direct and indirect effects of metformin on cancer” reused from 
“Understanding the benefit of metformin use in cancer treatment” by Dowling, R. J., 
Goodwin, P. J., & Stambolic, V. (2011). BMC Med, 9:33, figure 1. doi: 10.1186/1741-
7015-9-33. © 2011 Dowling et al; licensee BioMed Central Ltd. 
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In many cancer types, Insulin level is found to be elevated and the related receptor 
tyrosine kinase signaling pathway is upregulated (Quinn et al., 2013). Insulin causes 
activation of these receptors which send growth and survival signals to the cells through 
PI3/AKT pathway (Dowling et al., 2011). So, metformin may reduce tumor growth 
indirectly by reducing insulin dependent growth promoting signals to the cell (Dowling et 
al., 2011).On the other hand, the direct mechanism is independent on insulin and 
metformin may target different cancer cell pathways, including: AMPK-dependent 
pathway and AMPK-independent pathway (Dowling et al., 2011; Quinn et al., 2013). In 
AMPK dependent mechanism, metformin can work through affecting AMPK/mTORc1 
pathway to inhibit protein synthesis and arrest cell growth(Quinn et al., 2013). In this 
mechanism, metformin activates AMPK which in turn inhibits mTOR (the  mammalian 
target of rapamycin ), a major regulator of cell growth and metabolism (Dowling et al., 
2011; Quinn et al., 2013). Activation of AMPK can inhibit mTOR by two main 
mechanisms: it can cause phosphorylation of tuberous sclerosis complex2 (TSC2) which 
leads to buildup of Rheb-GDP (inactive form) and ultimately mTOR inhibition, or it can 
phosphorylate raptor ( a regulatory molecule bound to mTOR and a substrate for AMPK) 
which subsequently lead to inhibition of mTORc1(Quinn et al., 2013). mTORc1 controls 
several downstream targets to regulate protein synthesis, transcription process, and 
autophagy in the cell (Duran & Hall, 2012). mTORc1 activation leads to activation of 
S6K (ribosomal protein S6 kinase) and inhibition of 4E-BP1(eukaryotic initiation factor 
4E-binding protein-1), the two main downstream targets of mTORc1 (Duran & Hall, 
2012). S6k is important for protein synthesis, and 4E-BP1 is particularly important for 
controlling cell metabolism and proliferation (Duran & Hall, 2012). So, inhibition of 
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mTOR pathway through AMPK activation can lead to inhibition of cell proliferation and 
protein synthesis(Dowling et al., 2011). On the other hand, metformin can inhibit mTOR 
independent on AMPK activation by affecting REDD1 expression (regulated 
development and DNA damage response)  and Rag GTPase proteins (Quinn et al., 2013). 
Besides, it was shown that metformin treatment can be more toxic to p53 mutant cancer 
cells, in which metformin-induced AMPK activation can lead to autophagy or apoptosis 
depends on presence or absence of functioning p53. (Buzzai et al., 2007; Quinn et al., 
2013). Thus p53 mutant cancer cells may be more sensitive to energetic stress exerted by 
metformin. (Quinn et al., 2013). 
Furthermore, a recent clinical trial using metformin therapy in women with breast 
cancer, metformin demonstrated inhibitory effect on cancer cell growth evident by 
biological markers (Hadad et al., 2011). Likewise, nowadays several preclinical and 
clinical trials are being conducted to test the role of metformin, as a promising anticancer 
medication, on different cancer types (Ben Sahra et al., 2010; Quinn et al., 2013). 
1.3 Published Data:  
Despite the great efforts which have been conducted in last years to elucidate the 
effect of metformin on various cancer types, not much is known about its effect on 
neuroblastoma growth and metastasis. According to previous research published in 2006, 
AMPK was activated in SH-SY5Y cell line in response to metformin treatment (Garcia-
Gil et al., 2006). Besides, these cells demonstrated reduction in survival and early 
morphological changes suggestive of apoptosis, with significant effect was found 72 
hours post metformin treatment (Garcia-Gil et al., 2006).Besides, a published data in 
21 
 
2013 testing the effect of metformin and other mitochondrial inhibitors (MIBG and 
phenformin) on different neuroblastoma cell lines, metformin was able to destabilize 
MYC/MYCN, enhance histone H3 acetylation in neuroblastoma cancer cell lines, and 
promotes expression of  several genes encoded for biomarkers associated with favorable 
prognosis (Wang et al., 2014). 
1.4 Hypothesis and specific aims: 
In our research we propose that metformin, a relatively safe, effective and 
inexpensive medication, could be a good candidate for the treatment of pediatric 
neuroblastoma. In the current research, we focus mainly on studying the possible in vitro 
anticancer effects of metformin on two different human neuroblastoma cell lines, SH-
SY5Y and the chemo-resistant SKNBE(2). Our research is conducted under following 
specific aims: 
Specific Aim 1: to test the effect of metformin on neuroblastoma cells growth and 
survival.   
Specific Aim 2: to determine the effect of metformin treatment on the tumorigenicity of 
neuroblastoma cells. 
Specific Aim 3: to further investigate possible mechanisms underlie the antineoplastic 
effect of metformin on neuroblastoma cells including: AMPK, Akt, and Rho GTPases 
signaling pathways.                                                                                                             
                                                                                                                                             
                                                                                                                                          
22 
 
CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell lines and culture conditions:  
Human neuroblastoma cell lines SH-SY5Y and SKNBE (2) were obtained from 
the American Type Culture Collection (ATCC; Manassas, VA). Cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM ; HyClone Laboratories, South Logan, 
Utah) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, GA) and  
100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Antibiotic-
Antimycotic; Atlanta Biologicals, GA), and  allowed to grow at 37˚C in humidified 
incubator with 5% CO2. Similar preparation for complete culture medium was used to 
grow neuroblastoma cells for all experiments in this research. 
2.2 Metformin and Antibodies: 
Metformin Hydrochloride (MP Biomedicals; Solon, OH) was dissolved in a 
sterile triple distilled water to make 1 Molar stock solution, which is further diluted in 
culture media to obtain the desired concentrations (1,10, 20 mM), respectively, for each 
experiment. Monoclonal primary antibodies and the compatible secondary antibodies for 
western blot analysis and Immunofluorescence assay were obtained from the following 
sources: Cleaved Caspase-3 Rabbit Ab, Beta- Actin Rabbit Ab, p-AMPK alpha Rabbit 
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Ab, Total AMPK alpha Rabbit Ab, p-Akt Rabbit Ab, and total Akt Mouse Ab (Cell 
Signaling Technology, Danvers, MA) Beta- Actin Mouse Ab, goat anti-rabbit IgG-HRP 
Ab, goat anti-mouse IgG-HRP Ab, Secondary antibodies conjugated with fluorescein 
isothiocyanate (FITC) (Santa Cruz Biotechnology, Dallas, TX) 
2.3 Cell proliferation quantification using Trypan blue dye: 
Each cell line was cultured in 60 millimeter plates with density of 5×105 
cells/plate supplemented with complete culture medium. After 24 hours, the media were 
removed, and cells were treated with metformin 1, 10, 20 mM diluted in medium, while 
the control received complete medium without metformin. Cells were allowed to grow 
under humidified condition for 2, 4, 6 days for SH-SY5Y cells and 2 and 4 days for SK-
N-BE (2), respectively. At indicated time points, cells were harvested by trypsinization 
and centrifuged at 1200 rpm for 5 minutes to get a cell pellet. Cell pellets were suspended 
in 1xPBS and live cells (unstained cells) were counted under light microscope using 
hemocytometer and trypan blue dye (Sigma-Aldrich).  
2.4 MTT colorimetric cell viability assay: 
          According to manufacture protocol (Roche diagnostics corporation; Indianapolis, 
IN), 5×103 cells/well of each cell line were seeded in 96 wells culture plate in triplicate 
with complete culture medium. After 24 hours, the medium was removed and cells were 
treated with metformin (1, 10, 20 mM), respectively, diluted in 100 µl of complete 
culture medium, while the control received medium without metformin. Cells were 
treated for 2, 4, 6 days for SH-SY5Y cells and 2 and 4 days for SK-N-BE (2), and at time 
of analysis 10 µl/well of MTT (3-4,5-Dimethylthiazol-2-Yl-2,5-Diphenyltetrazolium 
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Bromide) labeling reagent was added and incubated at 37 ˚C for 4 hours, followed by 
overnight incubation with 100 µl/well of solubilization solution. Cell viability was 
measured based on the ability of active viable cells to yield formazan product (purple 
color) as a result of cleavage of the yellow Methylthiazol tetrazolium (MTT) salt (Roche 
diagnostics corporation). The resulting colored solution was read by spectrophotometer at 
550 nm (the absorbance of formazan product which is directly related to the density of 
live cells), while the background reference absorbance was read at 690 nm. 
2.5 Soft agar colony formation assay: 
 Approximately  5×104 cells/plate of each cell line were mixed with 0.35% 
agarose gel (Amersham) in DMEM medium supplemented with 10% FBS. The 
suspension (cells and 0.35% agarose gel) was laid on the top of a solidified bottom layer 
of 0.8% agarose gel supplemented with the same culture medium and plated in 35 
millimeter cell culture plates. After the top layer was solidified, the two-layer agarose gel 
plates (containing cells) were kept at 37ºC in a humidified incubator. After 24 hours, cells 
were treated with or without metformin (1, 10, 20 mM) diluted in 500µl /plate complete 
DMEM medium. Cells were fed each 4-5 days with DMEM medium containing 10% 
FBS with or without (for control) the indicated concentrations of metformin. After 45 
days, colonies were stained with 0.1% crystal violet dye and the number of colonies was 
counted under the light microscope. 
2.6 Immunofluorescence analysis: 
                  Each cells line was grown in Lab-tek II chamber slides (Thermo scientific) in 
complete culture medium with 10% FBS. After cells were reached 20-30% confluent, 
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they were treated with or without 20mM metformin diluted in medium and kept at 37C in 
a humidified incubator. At indicated time points, the growth medium was removed and 
cells were washed with 1x PBS and fixed with 4% paraformaldehyde in PBS for 
approximately 20 minutes. Cells then were permeabilized with 0.1% Triton X-100 in 
PBS for 10 minutes and washed again with 1x PBS. Cells were incubated with blocking 
reagent of 10% immunoglobulin free-bovine serum albumin ( Jackson Immune Research 
Laboratories, PA) in 1 x PBS for overnight at 4˚C. Cells were incubated for overnight 
with cleaved caspase-3 primary antibody in 2.5% IgG-free BSA/PBS at 4˚C. FITC (Santa 
Cruz Biotechnology, TX) secondary antibody in 2.5% IgG-free BSA/PBS was used to 
detect cleaved caspase-3 after 2 hours incubation at room temperature. Slides then 
washed with 1 x PBS followed by adding of antifade Vectashield mounting media 
(Vector Laboratories, CA), and the nucleus was counterstained with DAPI (4',6-
diamidino-2-phenylindole;Sigma). Signals for cleaved caspase3 and nucleus were 
visualized under fluorescence microscope (Nikon-E600, Tokyo, Japan). 
2.7 Western blots analysis: 
      Cells were plated in 100 millimeter plates with DMEM culture medium supplemented 
with 10% FBS. After they reached 20-30% confluent, cells were treated with metformin 
(1, 10, 20 mM) diluted in 10 ml complete culture medium for 4 and 6 days for SK-N-BE 
(2) and SH-SY5Y cells, respectively, while the control received culture medium without 
metformin. At indicated time points, cells were harvested and lysed in RIPA lysis buffer 
and protein concentration was estimated using bicinchoninic acid protein assay (BCA 
assay; Thermo scientific, Rockford, IL). Equal amount of protein samples were denatured 
by heating with Laemmli loading dye containing 2-Mercaptoethanol(Bio-Rad 
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laboratories; Hercules, CA). Protein samples were resolved by electrophoresis using 10-
14% Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis or SDS-PAGE (30% 
acrylamide/Bis solution, 1.5M Tris-Hcl buffer pH 8.8(Bio-RAD laboratories), 10% 
sodium dodecyl sulfate SDS (Biomedicals Inc), 10% Ammonium per Sulfate, 
Tetramethylethylenediamine or TEMED (Fisher BioReagents)). Proteins were transferred 
to polyvinyl difluoride (PVDF; Amersham, Buckinghamshire, NA) membrane and then 
blocked with 5% non-fat dry milk for 2 hours at room temperature or 10% Bovine serum 
Albumin or BSA for overnight at 4˚C.Western blots membranes were incubated with 
either monoclonal primary antibodies diluted in 2.5% nonfat dry milk/TBST (1:1000 
dilution) or 5% BSA/TBST (1:1000 dilution) for overnight at 4 ˚C. 
            After washing with 1xTBST, a compatible secondary antibody was added 
(1:2000-4000 dilution in milk or BSA/TBST) and incubated for 1-2 hours at room 
temperature followed by wash with 1xTBST. ECL substrate (Enhanced 
Chemiluminescence; Bio-Rad laboratories) were used to reveal protein of interest and the 
signal was detected using radiographic film (Thermo Scientific).  
2.8 Statistical analysis:  
Statistical analysis was performed using GraphPad InStat software (GraphPad 
Software, Inc. La Jolla, CA). For data from 3 experiments, the average results were 
calculated and the error bar represents the standard deviation of the mean. One-way 
ANOVA was performed followed by Tukey-Kramer test to compare significance among 
treated group relative to control (p-value < 0.05 was considered significant).   
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CHAPTER 3 
RESULTS 
3.1Metformin exerts growth and survival inhibitory effects on 
neuroblastoma cell lines: 
  To test the growth inhibitory effect of metformin on SH-SY5Y cell line and the 
chemo-resistant SK-N-BE2 cell line, cells were grown in complete culture media 
supplemented with 10% FBS in presence or absence of metformin (1,10,20 mM) for 6 
and 4 days, respectively. The results of viable cells count using trypan blue dye 
demonstrate that metformin significantly inhibit cell proliferation at concentrations of (10 
and 20 mM) in time and dose dependent pattern relative to control, in both cell lines, 
while no significant effect were found at the lower concentration (1 mM) (Figure3.1 
A&B). Besides, the morphological changes of treated cells were examined daily under 
light microscope and compared to the control. We noticed morphological changes 
suggestive of apoptosis at (10 mM and 20mM) metformin treated groups, which started at 
day 2 in SK-N-BE2 cells and at day 4 in SH-SY5Y cells, while more drastic changes 
were noticed at day 4 for SK-N-BE2 and day 6 for SH-SY5Y cells, when marked number 
of cells became rounded and started lifting, (Figure 3.1 C), as reported in our previous 
work (Kumar, Al-Sammarraie, DiPette, & Singh, 2014). To further confirm our results, 
MTT colorimetric assay was performed to check the enzymatic activity of both cell lines, 
which directly correlated with cell viability (Roche diagnostics corporation; Indianapolis,
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 IN). Our results show that metformin was significantly able to inhibit cells viability at 
(10 and 20 mM) in time and dose dependent manner for both N-MYC amplified and non 
N-MYC amplified cells. However, no significant effect on cell viability was noticed at (1 
mM) treated group compared to the control (Figure 3.2 A&B). 
3.2 Metformin inhibits the anchorage-independent colony formation of both 
neuroblastoma cell lines: 
In order to test the ability of metformin to inhibit anchorage-independent 
malignant growth of neuroblastoma cells in vitro, we monitored colony formation of SH-
SY5Y and SK-N-BE2 cells seeded on a two-layered agarose gel and treated with 
metformin at different concentrations (1, 10, 20 mM) ,versus the untreated control group, 
over 45 days. Cells were fed every 4-5 days with fresh complete medium containing the 
indicated concentrations of metformin, while control group received culture media 
without metformin. At indicated time point, the number of established colonies was 
counted under the light microscope, and the number of colonies in treated groups was 
compared relative to the control. Our preliminary data suggest that metformin was able to 
inhibit colony formation of neuroblastoma cells at (10 and 20 mM) respectively in both 
cell lines (figure 3.3A&B). However, no significant effect on colony formation was 
found at the lower concentration (1mM) treated group. 
3.3 Metformin induces apoptosis in neuroblastoma cell lines:  
In order to check the anti-survival effect of metformin on neuroblastoma cell 
lines, SK-N-BE (2) and SH-SY5Y cells were grown in presence or absence of 20 mM 
metformin for 4 and 6 days, respectively. At the indicated time points, 
immunofluorescent staining was performed using anti-cleaved caspase3 antibody, which 
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detect the active form of caspase3. Our results show that metformin was able to induce 
apoptosis through activation of caspase 3 in both cell lines reflected by the green 
cytoplasmic signal of the cleaved active form, especially when counter staining of the 
nucleus with DAPI was performed (Figure 3.4 A). Besides, western blot analysis was 
performed to detect cleaved caspase 3 band using whole cell lysates of SK-N-BE(2) and 
SH-SY5Y cells treated with 1,5,10, or 20 mM metformin, for 4 and 6 days respectively, 
compared to untreated control. Our results demonstrate that metformin induced marked 
activation of caspase 3 in both cell lines at (10 and 20 mM) revealed by western blot 
bands, while no difference was found at 1mM relative to control, (Figure 3.4.B), as 
indicated in our previous work (Kumar et al., 2014). 
 3.4Metformin’s anti-proliferative and anti-survival effects may be 
independent on AMPK and AKT pathways: 
To further check the possible pathways by which metformin could exert its 
antineoplastic effects, SK-N-BE (2) and SH-SY5Y were treated with(1, 10, 20 mM) 
metformin for 4 and 6 days, respectively, and the level AMPK phosphorylation was 
measured using western blot analysis of pAMPK (phosphorylated AMPK). We observed 
slight increase in the level of pAMPK in the treated group of both cell lines relative to 
control. We further measured the total AMPK to get the ratio of pAMK/total AMPK. Our 
results show that the level of phosphorylation of AMPK in both cell lines was statistically 
insignificant relative to the control, (Figure 3.5 A&B), as reported in our previous work 
(Kumar et al., 2014). Similarly, we checked the effect of metformin on Akt survival 
pathway, in which Akt activation is frequently associated with high stage neuroblastoma 
(Santo et al., 2013). Our preliminary data suggest that metformin treatment has no 
marked effects on pAkt or total Akt proteins expression, demonstrated by western blot 
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analyses of whole cell lysates of treated cells relative to control, (Figure 3.6), similar to 
previous work (Kumar et al., 2014).  
3.5 Metformin effect on Rho GTPases protein expression:  
Rho GTPases are small G-proteins belong to Ras superfamily and play vital role 
in cell growth and proliferation (Shang et al., 2012). Metformin anticancer effect noticed 
in many cancer types works mainly through inhibition of mTOR/S6k pathway, and S6k is 
regulated by Rho GTPases (Chou & Blenis, 1996; Dowling et al., 2011). In this study, we 
performed western blot analysis using whole cell lysates of SK-N-BE (2) and SH-SY5Y 
cells to detect a change in total  RhoA and Rac1 small GTPases proteins expression post 
metformin (1,10, 20 mM) treatment, for 4 and 6 days, respectively. Our initial data 
suggest that metformin markedly reduced total RhoA expression in both cell lines at 10 
and 20mM concentrations relative to control (Figure3.7A). Similarly, total Rac1 
expression was reduced in response to metformin (10 mM and 20 mM) treatment in SK-
N-BE(2), while no marked change was detected in SH-SY5Y total Rac1 protein 
expression compared to control (Figure3.7B). 
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Figure 3.1 The effect of metformin on neuroblastoma cells proliferation (A) Live cells 
count of SH-SY5Y cells treated with metformin (1, 10, 20 mM) for 6 days duration, N=3, 
error bars represent ± SD of the mean. (B)Live cells count of SK-N-BE2 cells treated 
with metformin (1, 10, 20 mM) for 4 days duration, N=3, error bars represent ± SD of the 
mean. (C) Representative images of morphological changes accompanied metformin 
treatment on both cell lines. 
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Figure 3.2 The effects of metformin on neuroblastoma cell viability (A) Cell viability 
estimated by MTT assay of SH-SY5Y cells treated with metformin (1, 10, 20 mM) for 6 
days duration, N=3, and error bars represent the ± SD of the mean. (B)  Cell viability 
estimated by MTT assay of SK-N-BE (2) cells treated with metformin (1, 10, 20 mM) for 
4 days duration, N=3, and error bars represent the ± SD of the mean. 
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Figure 3.3 The effects of metformin on neuroblastoma colony formation. (A) Number of 
colonies of SH-SY5Y cells treated with metformin for 45 days and expressed as fold 
change relative to control, N=triplicate, and error bar represent ±SD of the mean. (B) 
Number of colonies of SK-N-BE(2) cells treated with metformin for 45 days and 
expressed as fold change relative to control, N=triplicate, and error bar represent ±SD of 
the mean. 
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Figure3.4 Metformin induces apoptosis of neuroblastoma cell lines (A) 
Immunofluorescence staining for cleaved caspase 3 detection in SH-SY5Y and SK-N-
BE(2) treated with 20mM metformin for 6 and 4 days respectively. (B) Western blot 
analysis for cleaved caspase 3 in SH-SY5Y and SK-N-BE(2) cells treated with 1,5,10, or 
20 mM metformin for 6 and 4 days respectively, relative to control N=3. 
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Figure 3.5 The effect of metformin on AMPK activation in neuroblastoma cells: (A) 
Western blot analysis of AMPK (phosphorylated and total protein) in SH-SY5Y and SK-
N-BE (2) treated with 1, 10, or 20mM metformin for 6 and 4 days, respectively, relative 
to control (B) Corresponding signal density of the ratio of pAMPK /Total AMPK 
measured by Image J software, N=3, and error bars represent ±SD of the mean. 
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Figure 3.6 The effect of metformin on AKT activation in neuroblastoma cells. Western 
blot analysis of AKT (phosphorylated and total protein) in SH-SY5Y and SK-N-BE (2) 
treated with 1, 10,or 20mM metformin for 6 and 4 days, respectively, relative to control, 
N=1-2. 
 
 
 
 
 
 
  
 
 
37 
 
 
 
 
Figure 3.7 The effect of metformin on Rho GTPases protein expression in neuroblastoma 
cells: (A) Western blot analysis of RhoA total protein expression in SH-SY5Y and SK-N-
BE (2) treated with (1, 10,or 20mM) metformin for 6 and 4 days, respectively, relative to 
control, N=1-2. (B) Western blot analysis of Rac1 total protein expression in SH-SY5Y 
and SK-N-BE (2) treated with (1, 10, 20mM) metformin for 6 and 4 days, respectively, 
relative to control, N=1-2. 
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CHAPTER 4 
DISCUSSION 
Neuroblastoma is a heterogeneous tumor with combination of several molecular 
and genetic abnormalities (Davidoff, 2012).These genetic aberrations can develop both in 
primary tumor and after chemotherapy which make the tumor difficult and sometime 
unresponsive to the treatment (Tweddle et al., 2001; Van Roy et al., 2009). Despite the 
combination of different modalities for treatment of neuroblastoma, still the survival rate 
low for high-risk group (American Cancer Society, 2014). Besides, the current treatment 
for high risk neuroblastoma may depend on intensified chemotherapy, which itself can 
carry serious complications for patients(American Cancer Society, 2014). In recent years, 
several laboratory studies have been performed testing the effect of metformin on 
different cancer types, which demonstrate marked anti-cancer effect of metformin on 
different cancers both in vitro and in vivo (Quinn et al., 2013). Moreover, metformin is 
worldwide approved first line medication for treatment of type 2 diabetes, due to the fact 
that it is relatively safe with mild side effects and rare complication of lactic acidosis 
(Ben Sahra et al., 2010; Rojas & Gomes, 2013). Besides, in recent years, clinical trials 
using metformin treatment in children and adolescence with type 2 diabetes have been 
conducted and showed that metformin treatment reduce blood glucose level (fasting) and 
body weight, without evidence of severe side effects, such as  hypoglycemia or lactic 
acidosis(Rojas & Gomes, 2013). So, recently great work have been performed 
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 studying the effect of metformin therapy on various cancer types, however, there is not 
much known about the effect of metformin on neuroblastoma. 
In this study, in vitro experiments were performed to test the effect of metformin 
on neuroblastoma cell lines, as metformin relatively safe drug with remarkable in vivo 
and in vitro anticancer effects and, in some cancer types, works more effectively on p53 
deficient cancer cells (Ben Sahra et al., 2010; Quinn et al., 2013). In this research, 
metformin anticancer effect on neuroblastoma cells was conducted using two different 
cell lines to mimic the heterogenic nature of neuroblastoma : SH-SY5Y, a subline of SK-
N-SH cells derived from bone marrow aspirate of  neuroblastoma lesions, which is N-
myc non-amplified (Xie, Hu, & Li, 2010; Wang et al., 2014), and SK-N-BE(2), a cell line 
derived from bone marrow biopsy of relapsed neuroblastoma lesions, which is N-myc 
amplified and p53 mutant (loss of function mutation) (Tweddle et al., 2001; Wang et al., 
2014). We first tested the effect of metformin on cell proliferation and survival using low 
and high concentrations of metformin (1-20 mM), which is similar to in vitro 
concentrations used in other studies (Ben Sahra et al., 2010). Our results suggest that 
metformin at 10 and 20 mM was markedly able to inhibit growth and survival of both 
neuroblastoma cell lines, similar to our previous work (Kumar et al., 2014) and to many 
in vitro studies testing the effect of metformin on different cancer types, such as breast 
cancer and pancreatic carcinoma (Ben Sahra et al., 2010). 
In addition, we observed morphological changes in cells being smaller and 
rounded which were more marked at day 4 and 6 for SK-N-BE (2) and SH-Y5Y, 
respectively, as reported previously (Kumar et al., 2014). Our finding is similar to 
previous study when metformin was able induce morphological changes suggestive of 
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apoptosis in SH-SY5Ycells with more significant effect noticed after 72 hours from 
treatment (Garcia-Gil et al., 2006). Besides, in some in vitro studies, metformin was able 
to induce apoptosis such as in triple negative breast cancer with caspases activation (B. 
Liu et al., 2009). So, we performed immunofluorescence staining to checked the 
expression of cleaved caspase-3 protein, an apoptotic marker indicative of the active 
effector caspase-3 (Fan & Bergmann, 2010),  in 20 mM metformin treated SK-N-BE (2) 
and SH-SY5Y cells for 4 and 6 days, respectively, versus the control. Our results suggest 
that caspase-3 was activated in treated group which revealed by presence of green 
immunofluorescence cytoplasmic signals. We further confirmed our results by detecting 
cleaved caspase-3 band, using western blot analysis, and it was found to be markedly 
activated in 10 and 20 mM treated cells at same time points, as indicated in our previous 
work (Kumar et al., 2014). 
The next part of our study focused on understanding the molecular pathways by 
which metformin may work as anticancer medication. We used western blot analysis of 
whole cell lysates of SK-N-BE (2) and SH-SY5Y treated with metformin for 4 and 6 
days respectively, to check different possible pathways by which metformin could inhibit 
growth and/or survival of neuroblastoma cells, including: AMPK activation, AKT 
inhibition, and change in Rho GTPases protein expressions. These preliminary data could 
be helpful as a start point for our ongoing and future work exploring the anticancer effect 
of metformin on neuroblastoma. 
In many studies, metformin has been found to work through AMPK dependent 
pathway to inhibit cell growth of different cancer cell types (Dowling et al., 2011; Viollet 
et al., 2012). In previous study using SH-SY5Y neuroblastoma cell line, AMPK was 
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activated in these cells 3 hours post metformin treatment (Garcia-Gil et al., 2006). Our 
results demonstrate that AMPK phosphorylation in metformin treated cell lines for longer 
time periods was statistically insignificant compare to control (Kumar et al., 2014). 
However, further study is needed to test whether metformin inhibit AMPK acutely at 
early time points that might lead to inhibition of cell growth and survival. 
  On the other hand, several studies have shown that metformin may work through 
targeting AKT pathway, via AMPK dependent or independent mechanism. Xiaona Liu et 
al reported that metformin inhibits cell growth of Glioblastoma cells by promoting 
PRAS40 (AKT substrate) association with RAPTOR, which ultimately inhibited mTOR 
independent on AMPK activation (X. Liu et al., 2014). Besides, in vivo study testing the 
effect of metformin on prevention of tobacco induced lung cancer; metformin was able to 
inhibit AKT activation and other pathways in lung tissue independent on AMPK, leading 
to attenuation of lung tumorgenesis. (Memmott et al., 2010). However, Zakikhani et al 
show that metformin was able to induce apoptosis in breast cancer cells due to the effect 
of metformin on inhibition of AKT pathway, beside mTOR inhibition, through AMPK 
dependent mechanism (Zakikhani, Blouin, Piura, & Pollak, 2010).  AKT is a 
serine/threonine kinase which plays important role in regulation of cell growth and 
survival(Megison, Gillory, & Beierle, 2013). Akt activation has been found to be 
associated with high stage neuroblastoma, and found to be important for MYCN post-
translation stabilization; hence, it is important for cancer cell growth and proliferation 
(Santo et al., 2013). So, to test if metformin can inhibit AKT pathway in neuroblastoma 
cells, we checked pAkt expression using western blot analysis to see whether metformin 
treatment can inhibit this survival pathway to arrest growth and induce apoptosis. Our 
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preliminary data suggest that metformin works in an Akt-independent mechanism, as no 
marked change was noticed on pAKT protein expression in treated groups of both cell 
lines compared to control, similar to previous work (Kumar et al., 2014). 
Similarly, we tested the effect of metformin on Rho GTPases proteins expression, 
as they are pivotal signaling molecules involved in cell growth, cell cycle progress and 
metastasis. (Shang et al., 2012). Metformin is known to affect S6 kinase pathway, and 
this pathway is regulated by Rho GTPases (Chou & Blenis, 1996; Dowling et al., 2011). 
So, we tested whether metformin could be targeting Rho GTPases signaling to inhibit 
growth and survival of neuroblastoma cells. RhoA and Rac1 are small GTPases proteins 
belong to Ras superfamily and they are well regulated in the cell in response to different 
cell conditions (Shang et al., 2012). Upon activation, with aid of Rho guanine nucleotide 
exchange factors (GEFs), they switch from GDP-bound inactive state to GTP-bound 
active state (Shang et al., 2012). Rho GTPases activities, especially RhoA, have been 
found to be upregulated in various cancer types and associated with cancer metastasis and 
growth; hence, targeting this vital pathway that control cell growth has been conducted in 
recent research (Shang et al., 2012). Rac1 is a small GTPase protein which controls 
S6kinase activity that plays role in cell passage from G1 to S phase through cell cycle 
(Chou & Blenis, 1996). It is also important for regulation of cell migration and 
cytoskeleton organization(Dirat et al, 2014). In recent study testing the effect of 
metformin on metastasis of prostatic cancer cells in nude mice, metformin was able to 
inhibit Rac1 GTPases activity by affecting several upstream signaling pathways, which in 
turn reduced cancer cells migration and metastasis (Dirat et al, 2014). In our studies we 
checked whether metformin affect expression of Rac1 using western blot analysis. Our 
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preliminary data suggest that metformin was able to inhibit total Rac1 protien expression 
in SK-N-BE (2) cells, while no marked difference is found on Rac1protien expression in 
SH-SY5Y cells compare to control. Likewise, we checked the effect of metformin on 
Rho/ROCK pathway, which is important for cell proliferation, migration, differentiation, 
malignant transformation and apoptosis (Ohta et al., 2012). In a published data regarding 
human ovarian cancer cells, inhibition of Rho/ROCK pathway, using fasudil inhibitor, 
promoted the anticancer effect of cisplatin in these cell lines (Ohta et al., 2012). 
Similarly, we tested the effect of metformin on this vital pathway using western blot 
analysis to check the total RhoA protein expression in treated cells. Our results 
demonstrated that metformin reduces the total RhoA protein expression in both cell lines, 
which may play a role in its anticancer effects. However, further in vitro studies are 
important to test the effect of metformin on Rho GTPases activity by measuring the 
relative ratio of active protein form to the total expression. In conclusion, our results 
imply that metformin, a relatively safe drug with wide clinical applications, could be a 
promising anticancer candidate for treatment of neuroblastoma in the future.  
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APPENDIX A: PERMISSION LETTER 
 
 
 
